LCN2 and metabolic dysfunction-associated steatohepatitis: In the current study, using a murine model of progressive MAFLD pathology that represents closely nonalcoholic steatohepatitis (NASH), we show that there was a marked increase of Lcn2 in systemic circulation and in diseased livers.